EUVIMEDEUVIMED entdecken
Multizentrische Studie

Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan

Guan-Jhou Chen, Nan-Yao Lee, Mao-Sung Tsai, Sung-Hsi Huang, Miao-Hui Huang, Chi-Ying Lin, Bo-Huang Liou, Tung-Che Hung, Shih-Ping Lin, Li-Shin Su, Sui-Yuan Chang, Chien-Ching Hung iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf488 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Guan-Jhou Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, HIV Integrase Inhibitors, HIV-1. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Centers for Diseases Control, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance-associated mutations (RAMs) to second-generation integrase strand-transfer inhibitors (INSTIs) have been increasingly observed among people with HIV (PWH) who experienced virological failure on dolutegravir-based ART. However, data on dolutegravir resistance in the Asia-Pacific region remain limited, and data on RAMs during virological failure while receiving bictegravir-based ART are even more scarce.

Methods

In this multicentre, retrospective study in Taiwan, PWH with treatment failure on second-generation INSTI-based ART and successful amplification of the integrase gene were included. Data collected included HIV-1 subtypes, plasma viral loads (PVLs), CD4 counts and clinical characteristics. RAMs were identified using the 2025 IAS-USA mutation list and interpreted using the Stanford HIVdb algorithm.

Results

From 2016 to 2022, 73 and 127 PWH experienced treatment failure on bictegravir- and dolutegravir-based ART, respectively, and had successful genotypic resistance testing. Median PVL at failure was 4.7 log10 copies/mL, and median CD4 count was 225 cells/mm3, with no significant between-group differences. RAMs to second-generation INSTIs were detected in 5.5% (4/73) of bictegravir- and 4.8% (6/127) of dolutegravir-treated individuals (P = 0.33). Common RAMs included Q148H/K/R (3.5%), G140A/C/R/S (3.0%) and R263K (1.5%), with comparable distributions between the two groups. Among eight PWH retained in care, four achieved viral suppression after switching to salvage ART, and four with continuation of INSTI-based ART.

Conclusions

Although RAMs to second-generation INSTIs may be detected during treatment failure, the overall prevalence remains low for both dolutegravir- and bictegravir-based ART. Viral resuppression can be achieved through salvage therapy or continued use of second-generation INSTI-based regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsHIV-1Drug Resistance, ViralHeterocyclic Compounds, 4 or More RingsHumansPiperazinesPyridonesOxazinesTaiwanRetrospective StudiesMaleTreatment FailureFemaleViral LoadAdultMiddle AgedAmidesNaphthyridinesCD4 Lymphocyte CountMutationHIV Integrase

Substanzen

Heterocyclic Compounds, 3-RingPiperazinesPyridonesOxazinesHIV Integrase InhibitorsbictegravirAmidesNaphthyridinesHeterocyclic Compounds, 4 or More RingsHIV Integrase

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
  • Infection Control Room, Min-Sheng General Hospital, Taoyuan, Taiwan.
  • Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
  • Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.

ORCID-Profile: Chien-Ching Hung

Förderung

  • Centers for Diseases Control, Taiwan

Zitieren

APA

Chen, G. J., Lee, N. Y., Tsai, M. S., Huang, S. H., Huang, M. H., Lin, C. Y., Liou, B. H., Hung, T. C., Lin, S. P., Su, L. S., Chang, S. Y., & Hung, C. C. (2026). Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf488

Vancouver

Chen GJ, Lee NY, Tsai MS, Huang SH, Huang MH, Lin CY, et al. Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf488

BibTeX
@article{Chen2026,
  author = {Chen, Guan-Jhou and Lee, Nan-Yao and Tsai, Mao-Sung and Huang, Sung-Hsi and Huang, Miao-Hui and Lin, Chi-Ying and Liou, Bo-Huang and Hung, Tung-Che and Lin, Shih-Ping and Su, Li-Shin and Chang, Sui-Yuan and Hung, Chien-Ching},
  title = {Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf488}
}
Kostenlos starten →